MRK - Merck & Co., Inc.
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 76.69 |
| Open | 76.75 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1000 |
| Day's Range | 76.40 - 77.35 |
| 52 Week Range | 65.25 - 92.64 |
| Volume | 4,925,037 |
| Avg. Volume | 10,550,028 |
| Market Cap | 193.674B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 19.45 |
| EPS (TTM) | 3.94 |
| Earnings Date | Jul 31, 2020 |
| Forward Dividend & Yield | 2.44 (3.18%) |
| Ex-Dividend Date | Jun 12, 2020 |
| 1y Target Est | 93.00 |
Fair Value
Related Research
- Zacks
Merck's Keytruda Gets Priority Review for Lymphoma Indication
FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.
- Business Wire
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
- Yahoo Finance
Coronavirus update: Florida sees deadliest day yet as US cases spike, economy jitters grow
The U.S. saw yet another day of record coronavirus casualties on Thursday, led mostly by a relentless surge in the stricken Sun Belt region.
- Reuters
New $1 billion fund aims to steer antibiotic companies in tough market
The fund, led by the International Federation of Pharmaceutical Manufacturers & Associations, seeks to serve as a temporary solution until new legislation can offer a more permanent fix in the market. It aims to help shore up investment in smaller biotech companies after several large drugmakers, such as Sanofi SA <SASY.PA> bowed out of the antibiotics space. The initiative "gives these biotechs access to the kinds of capabilities that large pharmaceutical companies have, such as manufacturing and regulatory," said Silas Holland, head of external affairs for the fund and director of global public policy at Merck.
- Reuters
New $1 bln fund aims to steer antibiotic companies in tough market
A new $1 billion fund backed by 20 drugmakers including Merck & Co Inc and Pfizer Inc is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments, an industry group said on Thursday. Public health authorities have raised alarms about a looming health crisis, saying deaths from antibiotic-resistant bacteria could dwarf that from the coronavirus pandemic. The new fund, led by the International Federation of Pharmaceutical Manufacturers & Associations, has raised nearly $1 billion so far and aims to help shore up investment in smaller biotech companies after several large drugmakers, such as Sanofi SA bowed out of the space.
- Zacks
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.
- Reuters
Prominent plaintiffs' firms sought government bailout to stay afloat
Several prominent plaintiffs' law firms, known for striking large settlements with companies like German carmaker Volkswagen AG and Equifax Inc, were approved for loans that totaled tens of millions of dollars in government aid meant to help small businesses stay afloat during the coronavirus pandemic. San Francisco-based Lieff Cabraser Heimann & Bernstein, which has 100 lawyers and bills itself on its website as "among the largest law firms in the United States that only represent plaintiffs" was approved to receive between $2 million and $5 million under the Paycheck Protection Program, according to data released Monday by the U.S. Treasury Department and Small Business Administration. Steven Fineman, the firm's managing partner, said Lieff Cabraser used the loan to compensate lawyers and staff members and prevent layoffs.
- Business Wire
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Business Wire
Merck Announces Appointment of Organon & Co. General Counsel
Merck Announces Appointment of Organon & Co. General Counsel
- MarketWatch
Dow Inc., American Express share losses lead the way, but Dow flat
DOW UPDATE The Dow Jones Industrial Average is falling Wednesday afternoon with shares of Dow Inc. and American Express seeing the biggest declines for the blue-chip average. Shares of Dow Inc. (DOW) and American Express (AXP) are contributing to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 15 points (0.
- Yahoo Finance
Coronavirus update: US cases spike above 3M as WHO withdrawal draws more critics
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
- Yahoo Finance Video
Where COVID-19 vaccine trials stand
Dr. Fauci says he expects phase 3 vaccine trials to begin at the end of July. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss where vaccine trials stand.
- GuruFocus.com
Immunomedics: A Solid Cancer Research Play
The company has a strong pipeline of antibody-drug conjugates Continue reading...
- MarketWatch
Merck, Eisai to put experimental cancer combination in new clinical trial
Shares of Merck & Co. Inc. gained 0.1% in premarket trading on Wednesday after it received a complete response letter from the Food and Drug Administration for an application to approve Keytruda in combination with Eisai Co. Ltd.'s Lenvima for a new indication. The regulator said the data that was provided in the application for the investigational combination therapy as a first-line treatment for unresectable hepatocellular carcinoma didn't demonstrate "a meaningful advantage" over existing therapies. The companies plan to conduct a new Phase 3 trial, which is already fully enrolled. They are also testing the Keytruda/Lenvima combination in 17 other clinical trials. Merck's stock has declined 13.4% year-to-date. The S&P 500 is down 2.6%.
- Business Wire
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
- Business Wire
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Merck and Eisai Receive Complete Response Letter for KEYTRUDA plus LENVIMA as First-Line Treatment for Unresectable Hepatocellular Carcinoma
- Reuters
AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer
The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo. Lynparza, which can now be used to treat patients with a form of BRCA-mutated metastatic pancreatic cancer, leads a class of drugs known as PARP inhibitors that stop cancer cells from repairing themselves after being damaged by chemotherapy.
- Zacks
Merck (MRK) Stock Moves -1.08%: What You Should Know
Merck (MRK) closed the most recent trading day at $78.72, moving -1.08% from the previous trading session.
- Reuters
U.S. government awards Novavax $1.6 billion for coronavirus vaccine
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021. The award is the biggest yet from "Operation Warp Speed", the White House program aimed at accelerating access to vaccines and treatments to fight the coronavirus that causes COVID-19. "What this Warp Speed award does is it pays for production of 100 million doses, which would be delivered starting in the fourth quarter of this year, and may be completed by January or February of next year," Novavax Chief Executive Stanley Erck told Reuters.
- Business Wire
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Merck Announces New Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
- Simply Wall St.
How Many Merck & Co., Inc. (NYSE:MRK) Shares Do Institutions Own?
A look at the shareholders of Merck & Co., Inc. (NYSE:MRK) can tell us which group is most powerful. Institutions...
- Insider Monkey
Were Hedge Funds Right About Merck & Co., Inc. (MRK)?
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]
- Reuters
Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses
Wall Street is moving some bets on COVID-19 vaccines to large pharmaceutical companies with robust manufacturing capabilities, signaling that a love affair with small biotech firms might be ending after the sector’s best quarter in almost 20 years. Early signs of the shift came Wednesday, when positive data for one of Pfizer Inc’s COVID-19 vaccine candidates sent shares of the large U.S. drugmaker up more than 3%. Although the news had little effect on shares of Pfizer’s large rivals in the vaccine race, smaller peers Moderna Inc and Inovio Pharmaceuticals Inc, both of which have previously shown promising COVID-19 data of their own, ended down more than 4% and 25%, respectively.
- InvestorPlace
Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO
The biggest initial public offering of 2020 might surprise you. It's Royalty Pharma (NASDAQ:RPRX), which as the name suggests, owns royalties on drugs from other pharmaceutical companies. So far, it's been a winner: even with a recent pullback, RPRX stock trades 66% above its IPO price.Source: Shutterstock I covered Royalty Pharma on my Moneyline podcast just last week. But since then, the story has seen a bit of a change. After a sharp post-IPO rally -- at the high, the stock had doubled -- RPRX has pulled back. Shares are down almost 10% in the past few days, bringing valuation in.The pullback isn't surprising. Indeed, last week I predicted precisely such a move after the strong rally out of the gate. And I'd expect, and hope for, additional weakness. There's an intriguing story here -- but it's not quite perfect. A cheaper price certainly would help.InvestorPlace - Stock Market News, Stock Advice & Trading Tips An Introduction to RPRX StockEssentially, Royalty Pharma provides a form of financing to pharmaceutical companies, who always are looking for more capital and/or to reduce risk. Royalty Pharma gives drug developers cash up front in exchange for a long-term royalty. That royalty usually is a few percentage points of revenue.We've seen this model work elsewhere, with the mining industry a notable adopter. Sandstorm Gold (NYSE:SAND) and, in particular, Royal Gold (NASDAQ:RGLD) both have had success and driven solid returns for shareholders. * 7 Utilities Stocks to Buy With Reassuring Dividends But Royalty Pharma innovated in applying the royalty model to the pharmaceutical space. In its prospectus filed ahead of the IPO, Royalty Pharma said it had deployed some $18 billion since its founding in 1996. The company estimates that is more than half the total value of all such transactions worldwide.Obviously, Royalty Pharma is the industry's leading player. As a result, it's executed partnerships with global pharma's biggest players. Gilead (NASDAQ:GILD) is a significant partner, as Royalty Pharma collects revenue from that company's entire HIV (human immunodeficiency virus) franchise. RPRX also has exposure to blockbusters from Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ), among many others.That diversification helps the case for RPRX stock. So do extremely high operating margins. Excluding non-cash factors, in 2019 the company turned almost 90 cents of every dollar in revenue into operating profit. It's the drug developers who bear the cost of selling, marketing, and researching the drugs.Given market dominance, downside protection, and a seemingly reasonable valuation, the post-IPO enthusiasm toward Royalty Pharma seems to make some sense. Some Yellow Flags with Royalty Pharma StockThat said, there are a few reasons for caution. Those factors may have led to the pullback from post-IPO highs above $56.First, the company isn't quite as diversified as an investor might think. Royalty Pharma does have royalties on more than 45 approved therapies. But five of those drugs drive over half of revenue.We've seen "patent cliff" concerns hover over the likes of Gilead -- in fact, for Truvada, from which Royalty Pharma receives a royalty stream. AbbVie (NASDAQ:ABBV) and Celgene, now owned by Bristol-Myers Squibb (NYSE:BMY), have faced similar pressures. Royalty Pharma's diversification mitigates that issue somewhat, but doesn't entirely remove it.After all, Royalty Pharma should have new drugs coming from which it can generate royalties. The problem is that its "pipeline" (not really a pipeline in the sense of a developer, but you get the point) looks rather thin. The company only has exposure to three development-stage candidates.Those candidates do look intriguing, as they include an asthma treatment from AstraZeneca (NYSE:AZN) that could be approved next year. Still, there's a real risk that Royalty Pharma can't fill the hole created as current leaders mature.From a broad standpoint, Royalty Pharma's model is likely better than that of a pure-play pharma. But it's not perfect. And at this valuation, that could be a bit of a problem. Hoping for a PullbackIn this market, 21x earnings (which is what we're looking at based on 2020 figures) doesn't seem all that onerous. But by pharma standards, it's rather high.Gilead stock trades at less than 12x forward earnings, even with optimism toward its potential treatment of COVID-19. Pfizer is in the same ballpark. Abbvie and BMS are even cheaper.Owing to its model, Royalty Pharma should get a higher valuation. But this is a company with a market capitalization around $28 billion. Again, shares have soared since the IPO. Investors to at least some extent are onto the story.That story, however, isn't perfect. It's intriguing. It's unique. But not perfect.Personally, I think the valuation could reflect that a little better. Given the fade in recent sessions, it may well do so. RPRX is an obvious candidate for an investor's watch list. Until we see a cheaper price, however, that's probably as far as we can go.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Keep an Eye on Royalty Pharma Stock, 2020's Biggest IPO appeared first on InvestorPlace.
- Zacks
Why the Earnings Surprise Streak Could Continue for Merck (MRK)
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
